Patient-reported outcomes with belantamab mafodotin treatment in patients with triple-class refractory multiple myeloma

This article presents patient-reported outcomes (PROs) from the randomized phase II DREAMM-2 study of the effect of single-agent belantamab mafodotin demonstrated. The patients were treated with the approved dose of belantamab mafodotin (2.5 mg/kg q3w). Disease and treatment-related symptoms, health-related quality of life (HRQOL), functioning, and patient-reported ocular changes were assessed at baseline, during treatment, and at the end of treatment.